Can Supriya Life Sciences unlock its next leg of growth beyond APIs?
Published on: June 6, 2026, 6:30 a.m. | Source: The Indian Express
Over the last few years, Supriya Life Sciences has expanded beyond its traditional API business. By targeting markets dominated by Chinese suppliers and investing in formulations, contrast media APIs, peptides, and CDMO services, the company is increasing its presence across the pharmaceutical value chain. The key question is whether these initiatives can transform it into a diversified pharmaceutical player.
